The Cigna Group
Compensation Insight

How The Cigna Group Pays

The Cigna Group's A0 to A9 title crosswalk, from Representative through Advisor and Principal to Vice President and the C-suite, priced across 20 markets alongside Long-Term Incentive Plan performance shares, options and no ESPP, a $22.87M CEO package at 310:1, and 445 FY2025 H-1B filings.

~67,700 employees · NYSE: CI · The Cigna Group · Bloomfield, Connecticut · FY ends 31 December
Employees
~67,700
Worldwide headcount at 31 December 2025, down from roughly 73,500 a year earlier. The decline mixes portfolio actions with workforce reductions and is not a single layoff.
United States employees
57,263
Disclosed for pay-ratio purposes at 31 December 2025 against 9,164 non-United States employees. No city-level split is published.
FY2025 revenue
$274.9B
Up 11 percent year on year with shareholder net income of $6.0 billion. Second-quarter 2026 revenue rose 7 percent to $71.7 billion.
CEO total pay
$22.87M
David Cordani's 2025 Summary Compensation Table total, of which $13.93 million was stock awards and $3.40 million option awards.
CEO pay ratio
310:1
Measured against a $73,674 median employee identified from a global population after permitted de minimis exclusions.
Median employee pay
$73,674
The 2025 proxy median. An acquired pharmacy population of 1,284 employees was excluded from the determination.
2025 incentive pool
100% of target
The executive scorecard calculated to 107 percent and the People Resources Committee applied a seven-point negative adjustment.
H-1B average base
$145,950
Average offered base across FY2025 labour condition applications by Cignaevernorth Services, with 424 of 445 certified.
Locations
United States
United Kingdom
Belgium
Spain
Singapore
Hong Kong
United Arab Emirates
Australia
India
Kenya
1.00× base / 1.00× TC vs Bloomfield

Band Hierarchy

The Cigna Group publishes no company-wide grade or band table. What it does expose, consistently across career postings and visa filings, is a durable title ladder: Representative or Analyst, then Senior or Lead Analyst, Advisor, Senior Advisor, Principal or Director, Lead Principal or Senior Director, Vice President and the executive officer tier. The A0 to A7 tiers used here are an analytical crosswalk over those titles, not a Cigna grade system, and only the officer layers above them carry a company disclosure.

Service and analyst ladder — tiers A0 through A2

A2
Senior Analyst / Lead AnalystIC / first-line management · variable 7.5% · reported
Senior analyst, lead analyst, application development senior analyst, operations specialist, supervisor
A1
Analyst / Senior RepresentativeIC · variable 5% · reported
Analyst, business analyst, claims analyst, eligibility analyst, data analyst
A0
Associate / Representative / TraineeIC · variable 1.5% · reported
Associate representative, customer service representative, operations trainee, junior claims support

Professional and advisor ladder — tiers A3 through A5

A5
Principal / DirectorIC / Director · variable 20% · reported
Principal engineer, lead architect, clinical or program strategy director, functional leader, large-program owner
A4
Senior Advisor / Senior ManagerIC / Manager · variable 15% · reported
Senior advisor, architect, technical lead, senior clinical strategist, senior manager, multi-team manager
A3
Advisor / ManagerIC / Manager · variable 11.5% · reported
Software engineering advisor, underwriting advisor, clinical advisor, product advisor, delivery manager, program manager

Leadership ladder — tiers A6 through A7

A7
Vice PresidentLeadership · variable 45% · modeled
Vice president, regional or function head, business-unit executive, occasional enterprise fellow
A6
Lead Principal / Senior Director / Managing DirectorLeadership · variable 27.5% · modeled
Lead principal, enterprise architect, distinguished domain expert, senior director, managing director, major function or business leader

Disclosed executive layer

President and Chief Executive Officer
Brian C. Evanko from 1 July 2026; David M. Cordani through 30 June 2026
Fully disclosed in the proxy statement. Cordani is the 2025 principal executive officer for Summary Compensation Table and pay-ratio purposes; Evanko's package is disclosed as a forward target, not as realized pay.
Executive Chair
David M. Cordani from 1 July 2026
Disclosed as a $1.0 million base and $2.0 million annual incentive target with continued long-term incentive eligibility whose amount the committee sets each year.
Executive Vice Presidents and segment presidents
Ann M. Dennison as Chief Financial Officer, Nicole S. Jones as Chief Administrative Officer, Everett Neville for Strategy and Corporate Development
Only officers who qualify as named executives appear in the compensation tables. Other executive officers are visible through Section 16 filings alone.
Senior Vice Presidents and other officers
Jamie Kates as Chief Accounting Officer
No compensation table exists for this layer. Forms 4 disclose share movements and nothing about salary, target bonus or grant value.
Non-employee directors
The independent board
A governance package rather than an employment band: a $215,000 annual equity retainer and a $120,000 cash retainer, with individual 2025 totals generally in the mid $330,000 to $370,000 range.
VerifiedOnly the executive officer, executive chair, chief executive and non-employee director rows carry a company disclosure. Everything at or below Vice President is reconstructed from official job postings, employee salary submissions and visa wage records.

Track divergence

A0 to A2
Cash is effectively the whole package. Target variable pay runs 0 to 10 percent of base and public salary records for these titles show no stock at all. A supervisor or operations lead can appear at the top of A2, but the pay zone barely separates from the senior individual contributor.
A3 to A5
The Advisor family is where Cigna's professional ladder really begins and where the individual contributor and manager paths run side by side at similar money. Target variable pay climbs from roughly 8 to 15 percent at Advisor to 15 to 25 percent at Principal or Director, and equity remains selective rather than routine.
A6 to A7
Long-Term Incentive Plan participation plausibly becomes real here, and it is the single largest step in the package. Target variable pay reaches 20 to 35 percent at Senior Director and 30 to 60 percent at Vice President, and the modeled equity component overtakes base pay.
Executive officers and above
Equity is the instrument, not a supplement. The named executives' 2025 stock and option awards were 63 to 76 percent of reported total pay, and the chief executive's target mix is 60 percent strategic performance shares, 25 percent restricted stock and 15 percent options.

Hierarchy qualifications and legacy structures

  • Cigna and Evernorth job postings and H-1B filings expose the title ladder reliably, but no source in this bundle exposes the underlying grade codes. A tidy Band 1 to Band 10 reconstruction would be false precision, which is why the tiers here are labelled A0 to A7 and described as analytical.
  • A small number of employee discussions describe Advisor as Band 4. That is a single unverified data point and is not enough to rebuild a numbered system, so it is recorded rather than adopted.
  • The crosswalk is most reliable for technology, actuarial and analytics roles, where official posted ranges and visa wage records overlap. It is progressively less precise for clinical, sales, underwriting and network roles, where Cigna can place equivalent scope differently and posts fewer ranges.
  • Vice President, Senior Vice President, Executive Vice President and segment president are corporate titles rather than hidden grade numbers, and are treated here as title tiers rather than claimed as bands.
  • The Long-Term Incentive Plan's Prior Plan definition absorbs the legacy Cigna plans, the Express Scripts 2011 and 2016 plans, the Directors Equity Plan and the 1991 Stock Plan. That confirms harmonisation at the equity-plan level after the Express Scripts combination, but it is not evidence of a harmonised public HR grade map.
  • The chief executive, executive chair and named executive officer rows are excluded from the band table entirely. Their anchors are single global figures that appear identically in every city table in the source bundle, so pricing them by location would produce meaningless offshore cells.

Peer-level mapping

BandArchetypePeer mappingCaveat
A0Associate / Representative / TraineeElevance and CVS representative or coordinator; entry support in a technology companyCigna publishes no grade code for this tier, so the mapping is by observed scope in job postings rather than by any company crosswalk.Bloomfield median from observed entry-level service and operations postings and salary submissions; not an official Cigna grade.
A1Analyst / Senior RepresentativeHealth-services peer Analyst; roughly L2 or junior professional in a technology companyA team lead in a small operations group can sit at the top of this tier, so the management crossover is not a clean line.Bloomfield median triangulated from observed Cigna and Evernorth analyst titles and salary submissions.
A2Senior Analyst / Lead AnalystSenior or Lead Analyst at Elevance and CVS; L3 or mid-level professional in technologyCigna combines Senior Analyst and Lead Analyst into one pay zone in public postings even though they read as two title steps.Official United States postings run roughly $51,500 for Senior Analyst to $66,600–$111,000 for Lead Analyst; Levels.fyi reports about $97,700 and $111,000 total for the two titles.
A3Advisor / ManagerAdvisor or Manager at a health-services peer; senior individual contributor or first-line manager in technologyEmployee discussions sometimes call Advisor Band 4. That label is unverified and should not be quoted as a Cigna grade.Official Advisor postings start around $111,700; Levels.fyi reports about $133,000 total and H-1B Advisor medians run $130,775 to $149,000 by city.
A4Senior Advisor / Senior ManagerSenior Advisor or Senior Manager at a health-services peer; staff individual contributor or senior manager in technologyThis is the modal H-1B sponsorship tier, so its wage evidence is unusually dense for technology roles and unusually thin elsewhere.Official Senior Advisor postings start around $130,200; Levels.fyi reports about $190,000 total and Software Engineering Senior Advisor is the largest single H-1B title at 349 filings.
A5Principal / DirectorPrincipal or Director at a health-services peer; principal individual contributor or director in technologyEquity here is permitted by the Long-Term Incentive Plan but neither frequency nor a minimum level is disclosed, so the equity column is a directional envelope, not an entitlement.Official Director postings run $141,500 to $240,400; Levels.fyi reports Principal Engineer around $228,000 total. The equity figure is the midpoint of a $0 to $100,000 indicative range.
A6Lead Principal / Senior Director / Managing DirectorSenior Director or Managing Director at a health-services peer; senior principal or senior director in technologyThis is the tier where equity plausibly becomes a real part of the package, but the $50,000 to $500,000 range behind the equity column is an analytical estimate rather than a disclosed grant matrix.Official Lead Principal and Senior Director postings run $177,400 to $296,300. The equity figure is the midpoint of a $50,000 to $500,000 indicative range and is the least certain number in this row.
A7Vice PresidentVice President at Elevance, CVS or UnitedHealth; VP or group leader in technologyOnly base pay here is evidenced by official postings. The equity and bonus columns are modeled from executive plan design, and no Cigna disclosure covers Vice Presidents who are not named executive officers.Official Vice President postings run $203,600 to $371,100. Bonus is the midpoint of a 30 to 60 percent target range and equity the midpoint of a $250,000 to $2,500,000 indicative range.

Critical evidence warning

The Cigna Group does not publish salary ranges, band minimums or midpoints for ordinary employees, does not publish a broad variable-pay grid, and does not publish an equity eligibility threshold below its named executives. Every non-executive figure in this report is a third-party observation, an official posted range or a calibrated model around one, and should be used for orientation rather than quoted as a Cigna pay band. Where a figure genuinely does not exist in public, this report says so rather than filling the gap.


Compensation by Band — Bloomfield

Low / median / high annual values at 1.00× base and 1.00× total-compensation factors versus Bloomfield. Total equals base plus bonus plus annualized equity.

BandTitleBaseVariableTotal TCEquity
A0
Associate / Representative / Trainee
0–2 years · reported
$40K$54K1.5%
$48K
$40K$55K
A1
Analyst / Senior Representative
1–4 years · reported
$63K$86K5%
$78K
$66K$90K
A2
Senior Analyst / Lead Analyst
3–7 years · reported
$79K$107K7.5%
$100K
$85K$115K
A3
Advisor / Manager
5–10 years · reported
$109K$147K11.5%
$148K
$126K$170K
$5K
A4
Senior Advisor / Senior Manager
8–14 years · reported
$145K$197K15%
$209K
$178K$241K
$13K
A5
Principal / Director
10–16 years · reported
$170K$230K20%
$290K
$247K$334K
$50K
A6
Lead Principal / Senior Director / Managing Director
12–20 years · modeled
$211K$285K27.5%
$591K
$503K$680K
$275K
A7
Vice President
15–22 years · modeled
$257K$347K45%
$1.81M
$1.54M$2.08M
$1.38M
Official headquarters at 900 Cottage Grove Road · 7 reported band cellsReportedModeledVerifiedBase and total use a plus or minus 15 percent planning envelope around the median; equity uses plus or minus 25 percent. Anchor totals are rebuilt from base plus target bonus plus annualized equity, with the source bundle's notional employer benefit load removed.

Total Compensation Range by Band

Total compensation in Bloomfield across the employee bands. Proxy-disclosed executive cohorts are excluded so the employee bands stay readable.

A0$40K$55KA1$66K$90KA2$85K$115KA3$126K$170KA4$178K$241KA5$247K$334KA6$503K$680K$0$100K$200K$300K$400K$500K$600K$700K

Global Footprint & Pay Arbitrage

The Cigna Group reported approximately 67,700 employees at 31 December 2025, of whom 57,263 were in the United States. Bloomfield, Connecticut is the pay anchor. India is the largest disclosed workforce outside the United States even though its headcount is never published, and every other market is calibrated against the Bloomfield median.

~67,700
Employees at 31 December 2025, down from about 73,500
57,263 / 9,164
United States and non-United States employees disclosed
20
Markets modelled across 10 countries
20%
Of United States payroll invested in benefits in 2025

Office and market catalogue — calibration factors versus Bloomfield

LocationLikely office profilePresenceBaseTC
Bloomfield
United States · USD
Global headquarters, enterprise leadership and corporate functionsOfficial headquarters at 900 Cottage Grove Road1.00×1.00×
Denver
United States · USD
Clinical, technology and commercial roles in a higher-cost United States marketOfficial office directory1.00×1.00×
Philadelphia
United States · USD
Health services, pharmacy and corporate roles with a client-facing biasOfficial office directory0.99×0.99×
Hartford
United States · USD
Legacy Connecticut corporate and insurance talent market adjacent to the headquartersRegional coverage near the Bloomfield campus0.97×0.97×
Phoenix
United States · USD
Operations, member service and clinical deliveryOfficial office directory0.92×0.92×
Nashville / Franklin
United States · USD
EviCore utilisation management, clinical and operations rolesOfficial office directory0.90×0.90×
St. Louis
United States · USD
Evernorth and legacy Express Scripts technology and pharmacy hubOfficial office directory; 66 live openings on 26 August 20260.89×0.89×
London
United Kingdom · GBP
Regional, commercial, product and international-health leadershipOfficial office directory; United Kingdom total 813 employees at 31 December 20250.68×0.68×
Glasgow
United Kingdom · GBP
International-health operations, technology and professional rolesOfficial office directory; reported restructuring runs through 20270.57×0.57×
Greenock
United Kingdom · GBP
Customer service, claims and international-health operationsOfficial office directory; the strongest entry-level salary evidence in the bundle0.51×0.51×
Antwerp
Belgium · EUR
International-health operations and underwritingOfficial office directory; 226 employees in Belgium at 31 December 20250.90×0.90×
Madrid
Spain · EUR
International-health centre of excellence and the local Spanish insurance businessOfficial office directory; the careers page also identifies Barcelona0.49×0.49×
Singapore
Singapore · SGD
Asia-Pacific commercial, underwriting and regional managementOfficial office directory; 125 employees at 31 December 20250.86×0.86×
Hong Kong
Hong Kong · HKD
International-health sales, operations and regional managementOfficial office directory; 292 employees at 31 December 20250.74×0.74×
Dubai
United Arab Emirates · AED
Middle East regional, broker, clinical and commercial rolesOfficial office directory; country headcount not separately disclosed0.52×0.52×
Sydney
Australia · AUD
Very small international-health and client-management presenceOnly 8 employees in Australia at 31 December 2025; the table is a market model1.00×1.00×
Bengaluru
India · INR
Technology, analytics and international-health delivery hubCore Cigna Health Solutions India site; 51 live openings on 26 August 20260.16×0.16×
Hyderabad
India · INR
Evernorth innovation hub for technology, data, artificial intelligence and operationsOpened in 2024 and scaling; 85 live openings on 26 August 20260.16×0.16×
Mumbai
India · INR
Market-facing activity dominated by the ManipalCigna joint venture rather than direct Cigna Group payrollDirect Cigna Group headcount not disclosed; the ManipalCigna joint venture employs over 2,800 people separately0.17×0.17×
Nairobi
Kenya · KES
Cigna Africa claims, member service and regional operationsOfficial office directory; 468 employees in Kenya at 31 December 20250.12×0.12×

The company publishes no city-level headcount anywhere. The only geographic figures in the filings are the United States and non-United States split and the named small-country populations used for pay-ratio exclusions: the United Kingdom 813, Kenya 468, Hong Kong 292, Belgium 226, Singapore 125 and Australia 8. India was not on that exclusion list, which is the strongest available signal that its population is materially larger.

Bloomfield anchor medians — the basis of every modeled cell

BandBaseStockBonusTotal
A0$47K$0$700$48K
A1$74K$0$4K$78K
A2$93K$0$7K$100K
A3$128K$5K$15K$148K
A4$171K$13K$26K$209K
A5$200K$50K$40K$290K
  • The Bloomfield column is the anchor. A0 through A7 medians come from official United States posted ranges where they exist, backed by Levels.fyi Cigna records and Glassdoor and Indeed cross-checks where they do not.
  • United States city factors are narrow: Denver matches the headquarters, Philadelphia sits at 0.99, Hartford 0.97, Phoenix 0.92, Nashville and Franklin 0.90 and St. Louis 0.89. None of them shows level-dependent compression, so none carries a top-of-ladder factor.
  • India shows the widest spread in the bundle. Bengaluru base runs at about 16 percent of the Bloomfield anchor at the Representative tier and roughly 54 percent at Vice President, so the onshore multiple falls from around six times to under two times across the ladder.
  • Dubai and London are the other two markets with strong upward compression, moving from 0.52 to 0.99 and from 0.68 to 0.93 respectively. Antwerp, Singapore and Sydney compress in the opposite direction, sitting close to the anchor at entry level and falling back at senior levels.
  • Nairobi is the lowest-priced market in the model, running at about 12 percent of the anchor at entry and 26 percent at Vice President, and its evidence is employee-reported rather than posted, so it should be read as directional throughout.
  • Auckland appeared in the source bundle's location list but is excluded here. The bundle itself records that there is no confirmed direct Cigna Group office in the public locations list and that it was included only to satisfy a New Zealand comparison, which makes it a selector placeholder rather than a payroll market.

Model rules

  • Every modeled cell is the Bloomfield median multiplied by the city factor and then by the 26 August 2026 foreign-exchange snapshot. Local currency figures are rounded to sensible payroll units, so a United States dollar figure will not always reverse-calculate exactly.
  • The source bundle defined total compensation as base plus target variable plus a country benefits load plus modeled equity. That benefit load is employer cost, not pay, and has been stripped: every total in this report is base plus target bonus plus annualized equity only.
  • Target bonus is the midpoint of the tier's disclosed indicative range, and annualized equity is the midpoint of the tier's indicative grant range. Both midpoints are analytical, and the equity midpoint at A6 and A7 is the single least certain number in the model.
  • Base and total factors are identical for every city because the source bundle's only city calibration is a base-pay index. Its apparent divergence between base and total factors at senior tiers came from applying one global equity range to every market, which pulls senior offshore totals toward parity with the United States; that artefact has been removed.
  • The Vice President row is excluded from the range chart because its equity component is directional and would otherwise dominate the scale for every other tier.
  • Executive officer, executive chair and chief executive pay is carried in the executive section only. It is a global parent-company disclosure and is not a local pay range in any selected city.

Variable Pay & Annual Cash Incentive

There are two bonus systems and only one of them is public. Executives sit on the annual Executive Incentive Plan, whose scorecard, funding factor and committee discretion are disclosed in detail. Everyone else sits on country and role-specific annual plans whose targets and payout history the company does not publish at all, so the band targets below are analytical ranges rather than Cigna policy.

BandTargetMechanismRecent payout
A0
Associate / Representative / Trainee
0–3% of baseAnnual cash bonus where the role and country plan provide for one.Not publicly disclosed
A1
Analyst / Senior Representative
3–7% of baseAnnual cash bonus where the role and country plan provide for one.Not publicly disclosed
A2
Senior Analyst / Lead Analyst
5–10% of baseAnnual cash bonus where the role and country plan provide for one.Not publicly disclosed
A3
Advisor / Manager
8–15% of baseAnnual cash bonus. Indian offer discussions commonly describe about 10 percent variable at this level, but those reports are anecdotal.Not publicly disclosed
A4
Senior Advisor / Senior Manager
10–20% of baseAnnual cash bonus on a mix of business and individual outcomes.Not publicly disclosed
A5
Principal / Director
15–25% of baseAnnual cash bonus on a mix of business and individual outcomes.Not publicly disclosed
A6
Lead Principal / Senior Director / Managing Director
20–35% of baseAnnual cash bonus, with senior leaders increasingly assessed on enterprise measures.Not publicly disclosed
A7
Vice President
30–60% of baseAnnual Executive Incentive Plan or an equivalent senior incentive on enterprise, business and individual performance.2025 executive pool approved at 100 percent of target
Officers
SVP / EVP / Segment President / C-suite
50–100% of base, and 200% for the chief executiveAnnual Executive Incentive Plan. Individual awards may range from 0 to 200 percent of target and the committee may move the aggregate pool by up to 10 points.2025 formula 107 percent, less seven points of negative discretion, approved at 100 percent
ModeledVerifiedThe 2025 outcome is the clearest evidence in the filings that Cigna's executive bonus is not a formula. The scorecard calculated to 107.1 percent on the strength of revenue and specialty pharmacy growth, despite adjusted income from operations landing well short at 84 percent, and the People Resources Committee then cut seven points off the fund. The company also disclosed that the 2023 to 2025 average payout ran two percentage points below the calculated funding factor, so negative discretion is recurring rather than exceptional. For 2026 the weights change to 50 percent adjusted income from operations, 20 percent growth split evenly between revenue and specialty prescriptions, and 30 percent strategic priorities including employee engagement and operating effectiveness.

Executive incentive targets — percent of salary

President and Chief Executive Officer
200% of base
Brian Evanko's $2.6 million annual incentive target against a $1.3 million base from 1 July 2026.
Executive Chair
200% of base
David Cordani's $2.0 million annual incentive target against a $1.0 million base from 1 July 2026.
Chair and Chief Executive Officer in 2025
200% of base
Cordani's $3.2 million 2025 non-equity incentive payout against a $1.6 million base is exactly 200 percent, consistent with a pool approved at target.
Other named executive officers
Not publicly disclosed as a percentage
The proxy discloses the paid amounts but not each officer's individual target percentage, so the implied 50 to 100 percent range here is inferred from paid outcomes.

Named-executive outcomes

ExecutiveTargetPaidAttainment
David M. Cordani$3,200,000$3,200,000100% of a 200%-of-base target

Employee payout timing and history

No broad employee payout history exists in public. Official country career pages in the United Kingdom, Belgium, Spain, Australia and Kenya confirm eligibility to be considered for an annual bonus without ever stating a percentage. United States and India crowd reports describe an annual rather than monthly payout, commonly in March, with the percentage strongly dependent on title and role. Those reports are not a plan description and cannot support an enterprise payout series, so no historical payout percentage is shown for tiers A0 through A6.

Sales and special incentives

Sales incentives, spot bonuses and sign-on or retention awards exist in job-specific contexts and appear in individual postings, but no standard global schedule is published. Treat any quoted sales plan as a role-level negotiation rather than an enterprise structure.


Equity — RSUs, PSUs, Options & ESPP

Everything runs through one plan. The Cigna Group Long-Term Incentive Plan, amended and restated on 28 April 2021, is an umbrella that permits options, stock appreciation rights, restricted stock, restricted stock units, strategic performance shares and strategic performance units, but only for key employees, non-employee directors, consultants and advisers the committee selects. There is no broad employee stock purchase plan evidenced anywhere in this bundle.

The Cigna Group Long-Term Incentive Plan
Active
Verified
Amended and restated 28 April 2021. Umbrella plan authorising options, stock appreciation rights, restricted stock, restricted stock units, strategic performance shares and units, and other stock-based awards.
Reserve: 12,386,735 shares available for future issuance at 31 December 2024
Long-Term Incentive Plan exhibit and 2024 annual report
Strategic Performance Shares
Active, the principal executive vehicle
Verified
A dollar target converted to shares at the grant price over a three-year performance period, settling between 0 and 200 percent of target. The 2023 to 2027 grants used 50 percent adjusted income from operations per share and 50 percent relative total shareholder return; the 2026 to 2028 grants use a 70 and 30 split.
Reserve: Drawn from the single Long-Term Incentive Plan reserve
2026 proxy statement
Restricted stock and restricted stock units
Active
Verified
Time-based retention awards valued at the grant-date market price. The 2025 named executive grants used restricted stock rather than units. Exact vesting depends on the individual grant agreement and is not published.
Reserve: Drawn from the single Long-Term Incentive Plan reserve
2026 proxy statement and 2025 Form 10-K
Nonqualified stock options
Active
Verified
Exercise price equals the market price at grant, vesting generally runs one to three years and the maximum term is ten years. David Cordani's 2025 grant of 39,476 options carried a $305.855 exercise price against a $308.85 grant-date market price.
Reserve: Drawn from the single Long-Term Incentive Plan reserve
2026 proxy statement
Stock appreciation rights
Permitted by the plan but no current grant activity identified
Verified
Authorised for selected participants. No recurring grants appear in the 2025 named executive award table, so this is plan capacity rather than an active programme.
Reserve: Would draw from the single Long-Term Incentive Plan reserve
Long-Term Incentive Plan exhibit
Strategic Performance Units
Permitted by the plan
Verified
Unit target value is $75 unless the committee sets a different value. Whether a unit settles in cash or stock depends on the award terms.
Reserve: Would draw from the single Long-Term Incentive Plan reserve
Long-Term Incentive Plan exhibit
Legacy Cigna and Express Scripts plans
Closed to new grants and absorbed as prior plans
Verified
The Prior Plan definition covers the legacy Cigna long-term incentive plans, the Express Scripts 2011 and 2016 plans, the Directors Equity Plan and the 1991 Stock Plan. Historical awards remain outstanding for their holders only.
Reserve: No shares available for future issuance at the last verified disclosure
Long-Term Incentive Plan exhibit and 2024 annual report
  • The Long-Term Incentive Plan was the only open equity plan at the last verified disclosure. No other plan had shares available for future issuance at 31 December 2024.
  • The current unused pool at 31 December 2025 and the resulting utilisation rate could not be verified in the accessible public excerpts used for this report, and should not be inferred by subtracting grants: forfeitures, cancellations, share-counting rules and performance outcomes all replenish or consume the reserve differently.
  • This is a United States listed long-term incentive plan, not an Indian tax-qualified employee stock option scheme. Stock exchange allotment notices, SEBI insider-trading rules and takeover disclosures do not apply to the parent; SEC Forms 3, 4 and 5 and Rule 144 are the relevant filings.
  • No broad employee stock purchase plan appears in any source reviewed. For most of the workforce there is no self-directed way to acquire company stock at a discount.

Plan reserve and illustrative value

12,386,735
Shares available for future issuance
At 31 December 2024, the last pool size verified in an accessible filing.
$3.46B
Illustrative gross value of that authorisation
At the $279.32 share price on 26 August 2026. This is not accounting expense, an employee entitlement or the current unused balance.
0–200%
Strategic performance share payout range
Over a three-year performance period, with the relative return component capped at 100 percent if absolute shareholder return is negative.
$15.1M
Chief executive annual long-term incentive target
Brian Evanko's recurring target from 1 July 2026, split 60 percent performance shares, 25 percent restricted stock and 15 percent options.

Vesting — common reported employee schedule

Grant
0%
+Target dollar value converted to shares at the grant price · annual tranche
Year 1
0% of performance shares; options begin vesting
+Options generally vest across one to three years; performance shares do not vest early · annual tranche
Year 2
0% of performance shares
+Performance measurement continues across the full three-year period · annual tranche
Year 3
Performance period closes
+Adjusted income per share and relative total shareholder return are certified · annual tranche
Year 4
0% to 200% delivered
+Vesting and delivery occur in the first quarter after the performance period closes · annual tranche

Strategic performance shares are cliff-settled, not laddered: nothing is delivered until the three-year period closes and the committee certifies the outcome, after which the payout lands anywhere between zero and double the target. Restricted stock vesting depends on the individual grant agreement and is not published. Options carry a separate one to three year schedule and a ten-year maximum term. Dividend equivalents accrue where award terms provide, but their value still depends on how many shares are ultimately earned.

Eligibility by hierarchy level

  • Tiers A0 through A2 show no public evidence of any standard grant, and salary records for these titles generally show no stock at all.
  • Tiers A3 through A5 have no disclosed company-wide threshold. Select retention or new-hire awards may occur, with an indicative $0 to $100,000 range, but there is no reliable grant matrix and no entitlement should be assumed.
  • Tier A6 is where select key employee participation becomes plausible, with an indicative $50,000 to $500,000 range, granted periodically and conditioned on committee or management approval and continued service.
  • Tier A7 is likely to carry annual or periodic grants in an indicative $250,000 to $2,500,000 range, mixing performance and time-based equity, but no Cigna disclosure covers Vice Presidents who are not named executive officers.
  • At the executive officer tier equity is the core of the package, with disclosed named executive grants running from $2.6 million to $17.3 million of combined stock and options in 2025.
  • The single most consequential undisclosed fact in this report is the minimum level for Long-Term Incentive Plan eligibility. The plan says selected key employees; nothing in public says where that selection starts.

Indicative annual grant value by band — Bloomfield

BandAnnual value (USD)MedianShares at $279.32
A3$4K$6K$5K~1322
A4$9K$16K$13K~3456
A5$38K$63K$50K~134224
A6$206K$344K$275K~7381,231
A7$1.03M$1.72M$1.38M~3,6926,153

Annualized planning value (±25%), not the face value of every new-hire grant. Share equivalents use the $279.32 reference price at 26 August 2026 and ignore plan valuation rules and PSU performance. Highlighted rows are disclosed grant-date stock awards.

Named executive target equity

ExecutiveTargetUnits / structure
Brian C. Evanko
President and Chief Executive Officer from 1 July 2026
$15.1M annual, plus a one-time $3.5M transition award60% strategic performance shares, 25% restricted stock, 15% options
David M. Cordani
Executive Chair from 1 July 2026
Continued Long-Term Incentive Plan eligibility, amount not fixed in the filingSubject to committee action each year
David M. Cordani
Chair and Chief Executive Officer in 2025
$17.33M of 2025 grant-date value33,350 target strategic performance shares worth $10,528,971 with a 4,169 threshold and 66,700 maximum, 11,117 restricted shares worth $3,400,190 and 39,476 options worth $3,400,019
Brian C. Evanko
President and Chief Operating Officer in 2025
$6.71M of 2025 grant-date value$5,056,613 of stock awards and $1,650,055 of option awards
Nicole S. Jones
Executive Vice President and Chief Administrative Officer
$4.13M of 2025 grant-date value$3,300,015 of stock awards and $825,034 of option awards
Ann M. Dennison
Executive Vice President and Chief Financial Officer
$3.25M of 2025 grant-date value$2,600,010 of stock awards and $650,029 of option awards
VerifiedNo employee stock purchase plan is evidenced in any source reviewed for this report. That absence matters: at technology and consumer companies a discounted purchase plan is usually the one equity component an employee can size for themselves, and Cigna employees below the selective Long-Term Incentive Plan population appear to have no equivalent. Treat any claim of a Cigna discounted share plan as unverified until a company benefit page confirms it.

Executive Compensation

Two chief executives sit in this section and they must not be blended. David Cordani was Chair and Chief Executive Officer throughout 2025 and is the principal executive officer in the latest completed-year compensation tables. Brian Evanko became President and Chief Executive Officer on 1 July 2026, so his package appears in the filings as a forward target rather than as realized pay.

CEO total — David M. Cordani
$22.87M
Stock awards are 75.8% of the reported total; salary 7% and non-equity incentive 14%
14%
76%
Salary $1.60M
Incentive $3.20M
Equity $17.33M
Salary$1,600,000
Annual incentive paid$3,200,000
Stock awards$13,929,161
Option awards$3,400,019
Change in pension value$97,562
All other compensation$639,392
Reported total$22,866,134

Reading the package

On a target-mix basis Cordani's 2025 package was roughly 8 percent salary, 15 percent annual incentive, 46 percent strategic performance shares, 16 percent restricted stock and 15 percent options, with 92 percent performance-based. Salary was 7.0 percent of the reported total and combined stock and option awards were 75.8 percent. The stock figure is a grant-date accounting value, not money received: the performance share component can still settle anywhere between zero and double its target three years later. Personal aircraft use was the largest disclosed perquisite.

CEO-to-median-employee ratio
310:1
Median employee $73,674 · The 2025 median employee was selected from a global population after SEC-permitted de minimis country exclusions, which is how the United Kingdom, Kenya, Hong Kong, Belgium, Singapore and Australia populations came to be named individually in the proxy. An acquired pharmacy business population of 1,284 employees was also excluded. The 2024 and 2023 chief executive totals were $23,251,096 and $21,047,255, but the median-employee methodology may differ between years, so those should not be read as a like-for-like ratio trend..
Peer CEO comparison
The Cigna Group · David Cordani · 2025$22.87M
2026 proxy statement
Elevance Health · Gail Boudreaux · 2025$22.58M
2026 proxy statement
CVS Health · David Joyner · 2025$21.21M
2026 proxy statement
UnitedHealth Group · Stephen Hemsley · 2025$60.94M
2026 proxy statement

Three of the four cluster tightly between $21.2 million and $22.9 million, which is the real signal here: Cigna, Elevance and CVS pay their chief executives within about 8 percent of each other. UnitedHealth's $60.94 million is not comparable, because it is dominated by a one-time appointment option award of roughly $60 million and does not represent a steady-state pay level.


Named Executive Officers & Board

Named executive officer compensation for 2025 as filed in the 2026 proxy statement. Stock combines the stock award and option award columns; other combines the pension change and all other compensation columns.

David M. Cordani · Chair and Chief Executive Officer in 2025; Executive Chair from 1 July 2026$22.87M
Salary $1.60M · Cash incentive $3.20M · Stock $17.33M · Other $737K · Equity 75.8%
Brian C. Evanko · President and Chief Operating Officer in 2025; President and Chief Executive Officer from 1 July 2026$10.00M
Salary $1.07M · Cash incentive $2.15M · Stock $6.71M · Other $69K · Equity 67.1%
Nicole S. Jones · Executive Vice President, Chief Administrative Officer and Chief Human Resources Officer$5.96M
Salary $850K · Cash incentive $850K · Stock $4.13M · Other $131K · Equity 69.3%
Ann M. Dennison · Executive Vice President and Chief Financial Officer$4.69M
Salary $900K · Cash incentive $450K · Stock $3.25M · Other $91K · Equity 69.3%
Everett Neville · Executive Vice President, Strategy and Corporate Development$4.07M
Salary $750K · Cash incentive $650K · Stock $2.60M · Other $74K · Equity 63.8%

The 2025 cash incentive outcomes show how much individual differentiation sits inside a pool approved at target. Cordani was paid $3,200,000 against a $1,600,000 salary, exactly 200 percent. Nicole Jones was paid $850,000 against an $850,000 salary. Everett Neville was paid $650,000 against a $750,000 salary. Ann Dennison was paid $450,000 against a $900,000 salary, the lowest ratio in the group. The proxy does not publish an individual target percentage for anyone other than the chief executive, so those differences cannot be decomposed into target versus performance. What they do establish is that the enterprise pool landing at 100 percent tells you very little about what any individual received.

Board compensation framework

ElementAmountNotes
Annual equity retainer$215,000The larger half of the non-employee director package and the reason board pay tracks the share price.
Annual cash retainer$120,000Paid to every non-employee director regardless of committee service.
Lead independent director retainer$75,000An additional retainer on top of the standard cash and equity retainers.
Committee chair retainer$25,000Additional retainer for chairing a board committee.
Committee member retainer$0Ordinary committee membership carries no separate retainer.
Employee directorsNo separate compensationDirectors who are also employees receive nothing additional for board service.

Individual 2025 non-employee director totals were generally in the mid $330,000 to $370,000 range depending on committee leadership and other items. This is a governance package rather than an employment band and is excluded from the pay ladder in this report.

Regional heads and other officers

Only officers who qualify as named executives appear in the compensation tables. Senior vice presidents and other executive officers, including the chief accounting officer, are visible through Section 16 filings alone, which disclose share movements and nothing about salary, target bonus or grant value. There is no public compensation figure for any Cigna employee below the named executive officers other than the $73,674 pay-ratio median.


Insider Trades — SEC Forms 3/4/5

SEC Forms 3, 4 and 5 and Rule 144 notices are the relevant filings for The Cigna Group, which is listed on the New York Stock Exchange. Indian exchange, insider-trading and takeover filings do not apply to the parent and searching for them is a dead end.

DatePersonTransactionSharesPriceValue
2026-08-04
Nicole S. Jones
Executive Vice President and Chief Administrative Officer
Exercise
Shares acquired through an option exercise. The exercise itself and any subsequent sale are distinct events and should not be double counted.
15,346$192.02$2.95M
2026-06-12
Jamie Kates
Chief Accounting Officer
Sale
Open-market sale, the smallest disclosed disposal in the window.
899$298.61$268K
2026-05-12
David M. Cordani
Chair and then Chief Executive Officer
Sale
The largest single disposal in the window, filed seven weeks before the chief executive transition took effect.
201,878$292.82$59.11M
2026-03-02
Nicole S. Jones
Executive Vice President and Chief Administrative Officer
Sale
Open-market sale on the same day as a disposal by Everett Neville.
2,307$288.91$667K
2026-03-02
Everett Neville
Executive Vice President, Strategy and Corporate Development
Sale
Open-market sale. A prior quarterly filing disclosed trading plans for both Neville and Jones.
1,719$288.91$497K
2025-11-03
David M. Cordani
Chair and Chief Executive Officer
Purchase
The only open-market purchase in the window, at a price roughly 18 percent below the level of the May 2026 sale.
4,134$241.88$1000K
2025-10-03
Brian C. Evanko
President and Chief Operating Officer; Chief Executive Officer from 1 July 2026
Sale
Open-market sale nine months before taking the chief executive role.
5,368$300.00$1.61M
2025-08-15
Nicole S. Jones
Executive Vice President and Chief Administrative Officer
Sale
The largest disposal by an officer other than the chief executive in the window.
28,526$300.00$8.56M

Reading guide

Trading plansA second-quarter 2025 filing disclosed Rule 10b5-1 trading plans for Nicole Jones and Everett Neville covering shares, strategic performance share outcomes and options. Sales executed under a plan are scheduled in advance and should not be read as a same-day view on the business.
Exercises are not purchasesA Form 4 acquisition line arising from an option exercise records the conversion of an existing award, not new money going into the stock. Only the November 2025 Cordani line in this table is an open-market purchase.
Direction of the windowSeven of the eight filings in this window were disposals or exercises and one was a purchase, which is the normal pattern where equity is the dominant element of executive pay rather than a signal in itself.
JurisdictionThe parent files with the SEC. Indian exchange insider filings, takeover disclosures and promoter-group transactions have no application to The Cigna Group and will not produce a complete picture.

Benefits & Perks

Benefits are the part of a Cigna package that is best documented and, in the United States, economically largest. The company states that it invested approximately 20 percent of United States payroll in health, wellbeing and other benefits in 2025. Outside the United States the country career pages confirm what exists without ever quantifying it, so most non-United States rows here describe a benefit rather than its value.

United States

  • EligibilityDay-one benefit eligibility. Comprehensive benefit eligibility begins on the first day of employment rather than after a waiting period. [Verified]
  • Time offMinimum 18 paid time off days plus holidays. A floor rather than a schedule; the accrual pattern by service and grade is not published. A separate paid preventive-care day is also provided. [Verified]
  • HealthFour core medical plans, two dental options and vision. In-network preventive care is covered at 100 percent. The employer premium share and any health savings account seed are not disclosed. [Verified]
  • Retirement401(k) with a match after a one-year waiting period. Employee contributions can start immediately; the company match begins after one year of service and vests immediately. The current match formula is not stated. [Verified]
  • RetirementHistorical match formula of up to 5 percent. A 2023 plan filing described 100 percent on the first 4 percent and 50 percent on the next 2 percent with two-year vesting. The 2026 careers page supersedes the vesting term but does not restate the formula, so treat 5 percent as the last fully disclosed historical design rather than a current guarantee. [Conflicting]
  • WellbeingWellness incentives up to $550 employee and $350 spouse or partner. Earned incentives, plus an employee assistance programme available to the household. [Verified]
  • LeaveUp to eight weeks caregiver leave. Available after the eligibility period. Parental leave duration is not separately published. [Verified]
  • DevelopmentEducation programme. Tuition and education support is confirmed on the benefits page without a published annual cap. [Verified]

Global programs

  • Working patternHybrid and flexible arrangements where the role permits. Applied globally with role-level discretion. Clinical, pharmacy and member-service roles are the obvious exceptions. [Verified]
  • WellbeingEmployee assistance programme and wellbeing initiatives. Available across markets, with the household covered in several countries. [Verified]
  • DevelopmentGlobal learning platforms. Referenced everywhere; no global certification budget or annual cap is published. [Verified]
  • CommunityPaid volunteering and employee communities. Confirmed as global programmes without a published day allowance. [Verified]
  • EconomicsApproximately 20 percent of United States payroll invested in benefits. Covering medical and pharmacy, paid time off, life and disability, 401(k) and retirement-related benefits in 2025. Comparing base pay alone materially understates the value of a United States Cigna package. [Verified]
  • Not disclosedGlobal sabbatical, certification cap and internal rotation guarantees. None of these appears in any reviewed source and none should be assumed. [Not publicly disclosed]

Benefit fields not publicly quantified

The pattern across markets is consistent and worth naming: Cigna reliably tells you that a benefit exists and reliably does not tell you what it is worth. Outside the United States, only the £50 United Kingdom eyewear contribution and the Belgian allowance structure carry any number at all. Every retirement contribution rate, insurance sum and leave schedule outside the United States is undisclosed, so a non-United States offer should be evaluated on the written contract rather than on the careers page.


Performance Review & Pay Progression

Cigna publicly described moving away from traditional year-end ratings toward frequent performance conversations in 2014, and has published nothing since about what replaced them. There is no public rating scale, no distribution, no rating-to-increase matrix and no time-in-level standard, which makes progression the least evidenced part of this report.

Not publicly disclosed

Current broad employee performance rating labels are not publicly disclosed. The 2014 move away from year-end ratings is the most recent official statement located.
No forced distribution or calibration percentage is published. Employee discussions allege calibration or rank-and-stack behaviour in some units, which is not evidence of enterprise policy.
No official rating-to-increase matrix exists. Employee reports frequently cite low single-digit annual increases of roughly 1 to 3 percent, but that is anecdotal.
The annual review month and merit effective date are not publicly disclosed. Employee reports commonly describe outcomes in the first quarter with bonus payment in March.
No enterprise attrition rate is published. The 2025 executive scorecard referenced voluntary turnover and engagement outcomes without publishing a percentage.
Promotion increase percentages, time-in-level standards and probation or confirmation terms by country are not disclosed anywhere.
No company-wide 2025 or 2026 average salary increase announcement was identified in any reviewed source, and crowd reports are too fragmented to support an enterprise claim.

Modeled promotion planning timeline

BandYears to next scopePromotion hikeStatus
A01–2 years to A1 for an 8 to 15 percent base increaseNot disclosedModeled planning interval
A12–3 years to A2 for a 10 to 18 percent base increaseNot disclosedModeled planning interval
A22–4 years to A3 for a 12 to 22 percent base increaseNot disclosedModeled planning interval
A33–4 years to A4 for a 10 to 20 percent base increaseNot disclosedModeled planning interval
A43–5 years to A5 for a 12 to 25 percent base increaseNot disclosedModeled planning interval
A53–5 years to A6 for a 15 to 30 percent base increaseNot disclosedModeled planning interval
A6Highly selective to A7, typically 20 to 40 percent plus an equity resetNot disclosedModeled planning interval
A7Highly selective to the executive officer tier; the package is redesigned around equityNot disclosedModeled planning interval

Executive timing is the one part of the calendar that is documented: base salaries and target opportunities are reviewed annually by the People Resources Committee and annual equity grants are typically made in the first quarter. For everyone else there is no published calendar. The Hyderabad hub is a special case worth knowing about, because it opened in 2024 and early employee reports described an immature first appraisal cycle with some mid-year promotions and market corrections rather than a settled annual rhythm.

Pay progression evidence

Modeled progression, not Cigna policy: A0 to A1 typically takes one to two years for an 8 to 15 percent base increase; A1 to A2 takes two to three years for 10 to 18 percent; A2 to A3 takes two to four years for 12 to 22 percent; A3 to A4 takes three to four years for 10 to 20 percent; A4 to A5 takes three to five years for 12 to 25 percent; A5 to A6 takes three to five years for 15 to 30 percent; A6 to A7 is highly selective at 20 to 40 percent or more; and the step above Vice President is a package redesign in which equity becomes the dominant element rather than a percentage increase. The most consequential unquantified gap sits alongside this: posted market ranges are materially wider than the low single-digit merit increases employees report, which implies an external hire can enter above an internal incumbent at the same title. No company dataset quantifies that gap.


H-1B / LCA Visa Footprint — United States

Cignaevernorth Services is a steady rather than a heavy sponsor, and its filings are unusually senior: the title mix is dominated by Advisor and Senior Advisor roles rather than entry-level engineers. Labour condition application wages are guaranteed base salary only, so they exclude bonus, benefits and any equity and must never be compared with a total compensation figure.

FY2025 applications
445
424 certified, one denied and the remainder withdrawn or certified-withdrawn, up from 322 disclosed status rows in FY2024 and 327 in FY2023.
FY2025 average offered base
$145,950
Up from $142,298 in FY2024 and $136,262 in FY2023, a compound increase of about 3.5 percent a year.
FY2025 petition approval rate
99.4%
346 approvals against two denials across 348 adjudicated I-129 cases, with 193 of 194 approved in the FY2026 snapshot.
FY2026 median wage
$152,337
H1BGrader reports a 75th percentile of $165,547; a mixed 2025 and 2026 sample of 92 records showed a $151,757 median.

Dataset summary

DatasetResultInterpretation
MyVisaJobs employer profile445 FY2025 applications at a $145,950 average offered base, with 424 certifiedAlso the source for the historical title mix and for the 308 applications recorded by 18 August 2026 in the FY2026 snapshot.
H1BGrader salary pagesFY2026 median of $152,337 and a 75th percentile of $165,547Used for the headline median, which this report rounds to $152,000.
H1BData 2025 and 2026 mixed sample92 records with a $151,756.50 median58 percent of records fell between $150,000 and $200,000 and 41 percent between $100,000 and $150,000, which is a notably narrow distribution.
USCIS petition outcomes346 of 348 FY2025 adjudicated cases approvedPetition approvals and labour condition applications count different things and should not be added together.

City-level H-1B wage history

CityP25MedianP75Records
St. Louis, MO
FY2026 Software Engineering Advisor records. The legacy Express Scripts and Evernorth technology hub and the largest concentration in the title filings.
$123K$133,250$143K7
Morris Plains, NJ
FY2026 Advisor records. A New Jersey worksite that does not appear in the company's headline office list.
$133K$149,000$152K6
Raleigh, NC
FY2025 records. The highest median in the sample despite the smallest record count.
$165K$165,600$169K3
Plano, TX
FY2026 Advisor records from a Texas worksite.
$128K$130,775$135K4
Bloomington, MN
FY2025 city summary. The lowest median in the sample by a wide margin.
$90K$95,826$105K3

All-years aggregates. P25/P75 are rounded reconstruction values marked modeled; medians and record counts are the stronger fields.

Selected title / worksite records

TitleWorksiteProffered wageNotes
Software Engineering Senior AdvisorMultiple United States worksites349 historical filingsThe single largest sponsored title and the clearest evidence that Cigna sponsors at the senior individual contributor tier rather than at entry level.
Software Engineering AdvisorMultiple United States worksites157 historical filingsThe experienced technical individual contributor tier, mapping to A3 in this report.
Application Development Senior AdvisorMultiple United States worksites86 historical filingsA parallel senior application engineering family with the same seniority marker.
Software Engineering Senior ManagerMultiple United States worksites54 historical filingsThe only management title in the top six, which is itself a signal about where sponsorship sits.
Infrastructure Engineering Senior AdvisorMultiple United States worksites32 historical filingsRounds out a title mix that is entirely technology and entirely senior.

Reading the data correctly

  • Labour condition application wages are the guaranteed base salary the employer offers. Bonus, benefits and any equity sit outside them entirely, so a $152,000 visa median is not a $152,000 package.
  • The city rows here are small surfaced samples of three to seven records, not complete Department of Labor aggregations for those cities. They are evidence points rather than city medians.
  • Applications and petitions count different things. An application is a wage filing and a petition is an immigration decision, so the 445 and the 348 in these statistics are not two views of the same population.
  • Fiscal-year snapshots differ between aggregators, which is why the FY2025 average of $145,950 and the FY2026 median of $152,337 come from different sources and should not be treated as a single series.
  • The sponsored title mix is overwhelmingly Advisor-level technology work. Nothing in this dataset says anything about pay in clinical, pharmacy, underwriting or member service roles, which are the bulk of the workforce.

Key Nuances & Insights

01Titles are public, grades are not

The careers site and the visa filings expose a durable title ladder that is stable enough to plan a career against, but the underlying grade codes appear nowhere. A neat Band 1 to Band 10 reconstruction would be false precision. The one employee-reported code, Advisor as Band 4, is a single unverified point.

02The equity cliff is the structural fact of Cigna pay

Public salary records for ordinary technical roles show zero stock, while executive filings show equity at 63 to 76 percent of reported total pay. The Long-Term Incentive Plan covers key employees the committee selects, and the company has never said where that selection starts. Somewhere around senior director or vice president the package changes shape, and nobody outside the company can point to the line.

03There is no employee stock purchase plan

No source in this bundle evidences a discounted share purchase plan. For most of the workforce that means there is no self-directed route into company stock at all, which is a meaningful difference from the technology employers Cigna competes with for engineers in St. Louis, Hyderabad and Bengaluru.

04The executive bonus formula is not the executive bonus

In 2025 the scorecard calculated to 107.1 percent and the People Resources Committee cut it to 100 percent. The company also disclosed that the 2023 to 2025 average payout ran two points below the calculated funding factor. Negative discretion is the pattern, not the exception, so treat a strong scorecard year as a ceiling rather than a floor.

05A pool at target says nothing about an individual award

With the 2025 pool approved at exactly 100 percent, the named executives were still paid at very different rates against salary: Cordani 200 percent, Jones 100 percent, Neville about 87 percent and Dennison 50 percent. Individual awards may range from zero to 200 percent of target, so the enterprise number is not a personal forecast.

06United States benefits are roughly a fifth of payroll

The company states it invested approximately 20 percent of United States payroll in health, wellbeing and other benefits in 2025. Comparing a Cigna offer with a competitor on base pay alone understates it materially, and this report deliberately strips that load out of its total-compensation column so the pay comparison stays clean.

07Mumbai is a corporate-boundary trap

ManipalCigna is a joint venture with more than 2,800 employees and a broad branch network. Those people are not direct Cigna Group staff, are not in the 9,164 non-United States headcount and should not be assumed to follow parent-company equity or incentive policy. A Mumbai offer needs its employing entity checked before any of this report's parent-company structure is applied to it.

08Australia has eight employees

The proxy disclosed exactly eight Australian employees at 31 December 2025, which is why Australia appeared on the de minimis exclusion list. A detailed Sydney band table can only be a market model. The same caution applies in weaker form to Singapore at 125 and Hong Kong at 292.

09The proxy-year chief executive is not the current chief executive

Cordani's $22.866 million is the latest completed-year figure and drives the 310 to 1 ratio. Evanko has been chief executive since 1 July 2026 on a roughly $19.0 million recurring target. Quoting one as the other is the single easiest mistake to make with this filing, and the transition also raises the odds of retention arrangements across the senior layers.

10India is a capability hub, not a cost centre

Hyderabad opened in 2024 and is positioned explicitly around data, technology and artificial intelligence. Advisor compensation in India reaches 27 to 56 lakh rupees, well above traditional back-office benchmarks, and the base gap against the United States narrows from about six times at entry to under two times at vice president.

11The lateral premium is real and unquantified

Posted United States ranges are wide, for instance $141,500 to $240,400 for Director, while employees report annual increases of roughly 1 to 3 percent. Those two facts together imply an external hire can enter well above an internal incumbent at the same title. No company dataset quantifies the gap, which is precisely why it persists.

12Legacy Express Scripts is visible in the geography, not in the pay

The St. Louis concentration, the Evernorth naming and the Prior Plan definition in the incentive plan all show the integration. No public evidence supports separate ongoing compensation bands for the legacy population, so treat St. Louis as a Cigna market at a 0.89 factor rather than as a distinct pay system.

13The 401(k) match has two answers and only one is current

A 2023 plan filing described a maximum effective 5 percent match with two-year vesting. The 2026 careers page describes match eligibility after a one-year waiting period with immediate vesting and does not restate the formula. The vesting improved and the formula went dark, so the 5 percent number should be treated as the last fully disclosed historical design.

14Indian securities searches are a false trail

The parent is listed on the New York Stock Exchange. Indian exchange allotment notices, insider-trading filings and takeover disclosures do not apply to it. SEC Forms 3, 4 and 5, Rule 144 notices and Rule 10b5-1 plan disclosures are the complete picture.

Research control

Cigna's chief executive pay sits at the top of a very tight cluster: $22.87 million against Elevance Health at $22.58 million and CVS Health at $21.21 million, a spread of under 8 percent across the three. UnitedHealth's $60.94 million is not comparable because it is dominated by a one-time appointment option award. The pay ratio tells a different story from the absolute number: at 310 to 1 against a $73,674 median, Cigna's ratio is driven far more by its median employee than by its chief executive, and that median reflects a workforce weighted toward pharmacy, clinical and member-service roles rather than toward engineering.

Evidence classification

LabelMeaningExamples and permitted use
VerifiedA Cigna SEC filing, an official Cigna benefit or career page, or a government rule.Executive pay, the incentive scorecard, equity plan terms, board pay, headcount, country populations, benefits and foreign exchange rates.
ReportedA named third-party dataset with observable records, chiefly Levels.fyi, Glassdoor and the visa aggregators, or an official posted salary range.The Bloomfield anchor medians for tiers A0 through A6, the India observations and the H-1B wage distributions.
ModeledA Bloomfield anchor observation multiplied by a city calibration factor and a dated foreign exchange rate, inside a planning envelope.Every non-anchor city cell, the Vice President row and every equity midpoint above tier A2.
Not publicly disclosedNo reliable public evidence was found in any reviewed source.Official grade codes, equity eligibility thresholds, broad bonus targets and payout history, attrition, performance rating labels and most non-United States benefit values.

Explicit “Not publicly disclosed” index

Official company-wide grade or band numbers and any crosswalk between them and titles.
Country-by-country direct headcount for India, Spain and the United Arab Emirates, and city-level splits anywhere in the United States or United Kingdom.
Broad employee variable-pay targets by level and any actual payout history below the executive population.
The minimum hierarchy level for Long-Term Incentive Plan eligibility and any typical non-executive grant value.
The unused Long-Term Incentive Plan pool at 31 December 2025 and the resulting utilisation percentage.
India benefit providers, insurance coverage amounts, Provident Fund or pension enhancements and exact leave allowances.
Current broad employee performance rating labels, any distribution and any rating-to-increase matrix.
Enterprise and country-level attrition rates.
The current 401(k) match formula, the employer health premium share and any health savings account seed.
Reliable Cigna-specific salary samples for Australia, Kenya, Belgium and the United Arab Emirates at any level.

Known gaps and diligence before relying on a cell

  1. 1The source bundle defined total compensation as base plus target variable plus a country benefits load plus modeled equity. That benefit load is employer cost rather than pay, and it has been removed: every anchor total in this report is base plus target bonus plus annualized equity, which is why the Bloomfield A0 total here is $47,500 rather than the bundle's $57,000.
  2. 2The bundle applied a single global equity range to every city at tiers A3 and above, which pushed senior offshore total-compensation factors toward parity with the United States. That is an artefact, not a finding, so location factors in this report are taken from the bundle's base-pay city calibration and the total factor is set equal to it. Base and total factors are therefore identical for every market.
  3. 3The chief executive, executive chair and named executive officer tiers are excluded from the band table entirely. Their anchors appear identically in every city table in the source bundle, so interpolating them by seniority would have forced every offshore factor toward one and produced meaningless senior cells. They are carried in the executive section and the leadership layer instead. This is why the ladder ends at Vice President with eight rows rather than continuing to the C-suite.
  4. 4Auckland was in the source bundle's location list but is excluded here, because the bundle itself records that there is no confirmed direct Cigna Group office in the public locations list and that the market was included only for comparison.
  5. 5Mumbai is retained but is not a clean parent-company payroll market. The visible presence is largely the ManipalCigna joint venture, whose employees are not in the disclosed non-United States headcount, so the Mumbai column should be read as an Indian market reference rather than as a direct Cigna Group pay table.
  6. 6The equity midpoints at tiers A5 through A7 come from indicative ranges of $0 to $100,000, $50,000 to $500,000 and $250,000 to $2,500,000. Those ranges are analytical estimates from the source bundle, not disclosed grant matrices, and their midpoints carry the widest uncertainty of any number in this report.
  7. 7Target variable percentages for tiers A0 through A6 are midpoints of analytical ranges. Cigna publishes no bonus target for any non-executive level in any country, so no payout history is shown for those tiers rather than repeating a placeholder on every row.
  8. 8The last verified equity pool figure is 12,386,735 shares at 31 December 2024. The 2025 year-end balance could not be confirmed in accessible excerpts and must not be derived by subtracting grants.
  9. 9Australia's eight-person workforce, Singapore's 125 and Hong Kong's 292 mean those city tables are market models built on very thin Cigna-specific evidence. Kenya, Belgium and the United Arab Emirates carry the same caution.

FX rates used — 1 USD equals, snapshot 2026-08-26

0.734
GBP
0.8571
EUR
1.2692
SGD
7.8397
HKD
3.6725
AED
1.3924
AUD
95.31
INR
129.432
KES

Single-date conversion layer for comparability; it ignores payroll-date FX, tax, purchasing power, benefits valuation and hedging. Compensation intelligence, not legal, tax, investment, immigration or employment advice.

Source register — 18 sources

P1The Cigna Group 2026 Proxy Statement · SEC EDGAR · Filed 12 March 2026. Headcount, country populations, named executive compensation, the incentive scorecard, equity grants, board pay and the pay ratio.
P2The Cigna Group 2025 Form 10-K · SEC EDGAR · Filed February 2026. Revenue, headcount, stock compensation accounting and human capital disclosures.
P3Cigna Long-Term Incentive Plan, amended and restated · SEC EDGAR · Effective 28 April 2021. Plan purpose, eligible participant categories, award forms and the Prior Plan definition.
P4The Cigna Group Q1 2026 Form 10-Q · SEC EDGAR · Quarter ended 31 March 2026. Current grant agreement exhibits and employee-plan stock issuance.
P5The Cigna Group 2024 Annual Report · SEC EDGAR · Year ended 31 December 2024. The 12,386,735 shares available under the incentive plan, the last pool size verified in an accessible disclosure.
C1The Cigna Group United States employee benefits page · Company careers site · Accessed 26 August 2026. Paid time off, medical plans, 401(k) terms, wellness incentives, education support and caregiver leave.
C2The Cigna Group country career and location pages · Company careers site · Accessed 26 August 2026. Official office footprint and the country benefit summaries used for every non-United States region.
C3The Cigna Group second-quarter 2026 results · Company newsroom · 30 July 2026. Current chief executive, quarterly revenue and the raised 2026 outlook.
C4The Cigna Group full-year 2025 results · Company newsroom · 5 February 2026. FY2025 revenue of $274.9 billion and shareholder net income of $6.0 billion.
J1The Cigna Group live and archived job postings · Company careers site · Accessed August 2026. Official United States posted salary ranges and the recurring title ladder from Analyst to Vice President.
S1Levels.fyi Cigna compensation records · Levels.fyi · Accessed August 2026. United States technical title anchors and the observation that ordinary technical packages show no stock.
S2Levels.fyi Evernorth India compensation records · Levels.fyi · Accessed August 2026. India software engineering anchors, including a median package near 33.2 lakh rupees.
S3Glassdoor, Indeed, PayScale and Comparably salary pages · Crowd-sourced salary aggregators · Accessed August 2026. Cross-checks for India, the United States, the United Kingdom, Europe, Asia-Pacific and the Middle East, with varying sample sizes.
V1MyVisaJobs employer profile for Cignaevernorth Services · MyVisaJobs, from Department of Labor and USCIS data · Accessed 26 August 2026. Application counts, average offered base salaries, petition outcomes and the sponsored title mix.
V2H1BGrader and H1BData records for Cigna Evernorth Services · Department of Labor derived aggregators · Accessed August 2026. The FY2026 wage median and percentiles and the city wage samples.
F4SEC Forms 4 and Rule 10b5-1 plan disclosures · SEC EDGAR · August 2025 to August 2026. The eight insider transactions in this report and the trading plans disclosed for two officers.
N1Reuters and contemporaneous reporting · Reuters · 2025 to 2026. The leadership transition, the approximately 2,000 role reductions and the change to employee GLP-1 coverage.
FX1Reserve Bank of Australia reference rates and market cross-rates · Reserve Bank of Australia · 26 August 2026. The single foreign-exchange snapshot used for every conversion in this report.

Recent News & Workforce Trend

The dominant 2026 story is a leadership transition rather than a pay action. No company-wide salary increase or freeze was announced in any reviewed source, and the year-end headcount decline mixes portfolio changes with a disclosed reduction programme.

~73,500
2024 employees
Worldwide headcount at 31 December 2024.
~67,700
2025 employees
Down about 5,800 year on year. The decline includes portfolio actions as well as workforce reductions and should not be read as a single layoff.
57,263 US / 9,164 non-US
2025 split employees
Disclosed for pay-ratio purposes, with the United Kingdom at 813, Kenya 468, Hong Kong 292, Belgium 226, Singapore 125 and Australia 8.

India is the conspicuous absence from that list. It was not among the small-country populations excluded on a de minimis basis, which is the strongest available signal that the Indian workforce is materially larger than any of the named markets, yet the company has never published an India headcount. The only India-specific activity signal in the bundle is live job openings: 85 in Hyderabad and 51 in Bengaluru on 26 August 2026, against 66 in St. Louis.

30 Jul 2026
Second-quarter revenue rose 7 percent to $71.7 billion and the outlook was raised

Adjusted operating income was $2.1 billion. Stronger results improve incentive funding capacity but carry no payout promise, because the scorecard still passes through committee discretion.

Company newsroom
1 Jul 2026
Brian Evanko became President and Chief Executive Officer

David Cordani became Executive Chair. Evanko's target package is a $1.3 million base, a $2.6 million annual incentive target and a $15.1 million annual long-term incentive target, plus a one-time $3.5 million transition equity award.

2026 proxy statement
12 Jun 2026
Chief Accounting Officer sold 899 shares at $298.61

The smallest disclosed disposal in the twelve-month window, filed shortly before the chief executive transition took effect.

SEC Form 4
2 Jun 2026
Employee plan stopped covering GLP-1 drugs for weight loss

Coverage ended on 1 July 2026 while diabetes treatment remained covered. This is a material change to the value of the United States benefit package and one of the few benefit design changes that can be dated precisely.

Reuters
12 May 2026
David Cordani sold 201,878 shares for about $59.1 million

The largest single insider disposal in the window, at $292.82 a share and seven weeks before he moved from Chief Executive Officer to Executive Chair.

SEC Form 4
28 Feb 2026
Approximately 2,000 global roles reduced

The company announced reductions of less than 3 percent of the workforce, targeted for completion by the end of February. This is a subset of the roughly 5,800 year-end headcount decline, not the whole of it.

Reuters
5 Feb 2026
FY2025 revenue reached $274.9 billion, up 11 percent

Shareholder net income was $6.0 billion. The 2025 executive incentive scorecard calculated at 107 percent on this result set and was approved at 100 percent of target after committee discretion.

Company newsroom
31 Dec 2025
Worldwide headcount fell to approximately 67,700

Down from roughly 73,500 a year earlier. The proxy disclosed 57,263 United States and 9,164 non-United States employees for pay-ratio purposes.

2026 proxy statement and 2025 Form 10-K
3 Nov 2025
David Cordani bought 4,134 shares on the open market for about $1.0 million

The only open-market purchase by an insider in the window, at $241.88 a share, roughly 18 percent below the price at which he sold in May 2026.

SEC Form 4
15 Aug 2025
Nicole Jones sold 28,526 shares for about $8.6 million

At $300.00 a share, the largest disposal by an officer other than the chief executive. A second-quarter 2025 filing had disclosed a trading plan covering her shares, performance share outcomes and options.

SEC Form 4
13 Mar 2025
Leadership structure changed ahead of the succession

Brian Evanko became President and Chief Operating Officer and Ann Dennison became Chief Financial Officer, changing the executive benchmarking and succession context fifteen months before the transition.

Company newsroom
1 Jan 2025
Customer satisfaction and employee engagement stayed in the executive scorecard

Together they carried 25 percent of the 2025 annual incentive weighting and both landed at target. For 2026 they are folded into a 30 percent strategic priorities component alongside operating effectiveness.

2026 proxy statement
Last updated 2026-08-27